Morphine combined ketamine with patient control subcutaneous analgesia in the management of moderate and severe pain in advanced cancer patients / 中国基层医药

ABSTRACT

Objective To observe the analgesic effects and safety of morphine combined low-dose ketamine with patient control subcutaneous analgesia(PCSA) for patieats with moderate to severe late cancer pain. Methods 60 patients with moderate to severe late phase cancer pain were randomly average divided into two groups (group Ⅰ and group Ⅱ). 30 patients of group Ⅰ were treated with morphine PCSA and 30 patients of group Ⅱ were treated lowdose ketamine plus morphine PCSA,respectively. The VAS(Visual Analogue Scale) of pain scores were evaluated after treatment 1 h、24 h、48 h. Effects and the rate of side effects were also comparred. Results There was no significant difference in VAS pains scores in each period. Morphine dosage in group Ⅰ (56.43 mmg) was significantly more than that in group Ⅱ (31.23mg) (x~2 =6. 18,P ＜0.05). Group ⅡThe incidence of nausea or vomiting was 4cases (13.3%) ,constipation was 2cases(6. 7%) ,drowsiness was 2cases(6. 7%) ,skin titillation was 0(0.0) ;but Group Ⅰ of it was 21 (70.0%), 18 (60.0%) ,9 (30.0%), 8 (26. 7%), The incidence of group Ⅱ was lower than group Ⅰ .Conclusion Small dosage ketamine combined with morphine patient control subcutaneous analgesia (PCSA) approach appears to provide a safe and effective method for advanced cancer patients with moderate to severe pain.